News

World Vaccine Congress 2018

26 March 2018

Meet us at the World Vaccine Congress in Washington DC, USA, 3-5 April 2018.

BIO Europe Spring 2018

19 February 2018

2A Pharma is overwhelmed by the positive responses we received from potential partners and collaborators at BIO-Europe Spring 2018. The conference was a resounding success from our perspective and we are looking forward to continuing the many exciting conversations that were started.

Press Release: 2A Pharma AB Raises SEK 27 Million and Signs Exclusive Worldwide License Agreement

16 January 2017

2A Pharma AB Press Release 2017-01-16

Article about 2A Pharma in MedWatch

16 January 2017

The following article was published in Danish pharma industry publication MedWatch on 16 January 2017.

http://medwatch.dk/secure/Medicinal___Biotek/article9288529.ece

Exclusive Worldwide License Agreement

20 December 2016

Medigene AG today announced that it has granted an exclusive, worldwide license for the development and commercialization of its preclinical stage adeno-associated virus like particles (AAVLPs) technology to 2A Pharma AB.

Read the full press release here.

First Financing Round Closed

19 December 2016

2A Pharma AB today closed its first financing round, raising SEK 27 million from private angel investors. This new capital will enable us to take our first project, the AAVLP-HPV vaccine, through to the end of phase I clinical studies. We are grateful for our investors’ support and trust.

2A Pharma AB is a Reality

12 December 2016

2A Pharma AB was incorporated in Sweden on 12 December 2016. Søren Nielsen, CEO: “This marks the formal beginning of a new exciting venture and the team is very excited about the journey ahead.”